topicAlpha Lipoic Acid Cognition Randomized Trial
claimObjectives This review aims to critically synthesize mechanistic, preclinical, and clinical evidence on α-lipoic acid and biotin as candidate neuroprotective agents in neurodegenerative diseases, with emphasis on shared signaling pathways, therapeutic potential, generally favorable safety profiles, and translational limitations.
evidence level4
citationAguilera-Méndez A (2026)
sourceAlpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives.
topicAlpha Lipoic Acid Cognition Randomized Trial
claimThe evidence was qualitatively analyzed with attention to biological plausibility, consistency across models, and clinical relevance.
evidence level4
citationAguilera-Méndez A (2026)
sourceAlpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives.
topicAlpha Lipoic Acid Cognition Randomized Trial
claimIn contrast, clinical evidence remains heterogeneous, with more extensive evaluation of biotin in progressive multiple sclerosis and more limited or exploratory findings for ALA across neurodegenerative disorders.
evidence level4
citationAguilera-Méndez A (2026)
sourceAlpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives.
topicAlpha Lipoic Acid Cognition Randomized Trial
claimBackground Neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis, represent a major global health burden and share convergent pathogenic mechanisms, such as mitochondrial dysfunction, oxidative stress, neuroinflammation, calcium imbalance, and neuronal loss.
evidence level4
citationAguilera-Méndez A (2026)
sourceAlpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives.